Literature DB >> 15877296

Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease.

Takahisa Kawano1, Takako Saito, Takanori Yasu, Tomoyuki Saito, Tomohiro Nakamura, Kazuyuki Namai, Hiroyuki Tamemoto, Masanobu Kawakami, Muneyasu Saito, San-e Ishikawa.   

Abstract

Adiponectin is an adipose-derived cytokine, and it is suggested that hypoadiponectinemia increases the prevalence of ischemic heart disease (IHD). The present study was undertaken to determine serum adiponectin levels in patients with arteriosclerosis obliterans (ASO) and IHD. Forty-nine patients with ASO and 49 age-, sex-, and body mass index-matched control subjects were examined. The diagnosis of ASO was derived from an ankle brachial index of less than 0.90 and stenotic or obstructive change in angiogram. Ischemic heart disease was diagnosed by ischemic or stenotic change in ECG, treadmill, or coronary angiogram. Serum adiponectin level was 8.6 +/- 0.9 microg/mL in the patients with ASO, a value significantly less than that of 12.4 +/- 1.0 microg/mL in the control subjects ( P < .01). Next, we subgrouped the subjects into 4 groups according to the presence of ASO and IHD. Serum adiponectin levels were 9.4 +/- 1.5 and 10.2 +/- 1.6 microg/mL in the subjects with ASO (n =23) and those with IHD (n = 13), respectively. It was further reduced to 7.9 +/- 1.2 microg/mL in the subjects having both ASO and IHD (n = 26), a value significantly less than that of 13.2 +/- 1.4 microg/mL in the control subjects (n = 36; P < .05). Serum high-density lipoprotein cholesterol was significantly less in the subjects with ASO than in the control subjects (42.1 +/- 1.7 vs 48.5 +/- 2.0 mg/dL; P < .05), but there were no differences in blood pressure, total cholesterol, low-density lipoprotein cholesterol, triglyceride, and uric acid levels. The present results indicate that a reduction in serum adiponectin level is associated with the prevalence and magnitude of systemic atherosclerosis including IHD and ASO.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877296     DOI: 10.1016/j.metabol.2004.12.009

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  12 in total

1.  Adiponectin inhibits oxidative/nitrative stress during myocardial ischemia and reperfusion via PKA signaling.

Authors:  Yanqing Zhang; Xiao-Liang Wang; Jianli Zhao; Ya-Jing Wang; Wayne Bond Lau; Yue-Xing Yuan; Er-He Gao; Walter J Koch; Xin-Liang Ma
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-10-15       Impact factor: 4.310

2.  Race-ethnic differences in adipokine levels: the Study of Women's Health Across the Nation (SWAN).

Authors:  Unab I Khan; Dan Wang; Maryfran R Sowers; Peter Mancuso; Susan A Everson-Rose; Philipp E Scherer; Rachel P Wildman
Journal:  Metabolism       Date:  2012-03-22       Impact factor: 8.694

Review 3.  The evolving role of adiponectin as an additive biomarker in HFrEF.

Authors:  Tahnee Sente; Andreas Gevaert; An Van Berendoncks; Christiaan J Vrints; Vicky Y Hoymans
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 4.  Direct effects of adipokines on the heart: focus on adiponectin.

Authors:  Min Park; Gary Sweeney
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

5.  Globular adiponectin counteracts VCAM-1-mediated monocyte adhesion via AdipoR1/NF-κB/COX-2 signaling in human aortic endothelial cells.

Authors:  Francesco Addabbo; Carmela Nacci; Leonarda De Benedictis; Valentina Leo; Mariela Tarquinio; Michael J Quon; Monica Montagnani
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-09-06       Impact factor: 4.310

6.  Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism.

Authors:  Koji Ohashi; Noriyuki Ouchi; Kaori Sato; Akiko Higuchi; Tomo-o Ishikawa; Harvey R Herschman; Shinji Kihara; Kenneth Walsh
Journal:  Mol Cell Biol       Date:  2009-04-27       Impact factor: 4.272

7.  Serum adiponectin and markers of endothelial injury in hemodialysis patients with arteriosclerosis obliterans.

Authors:  Osamu Saito; Takako Saito; Kousuke Okuda; Kenji Okuda; Atsushi Kotoda; Tetsu Akimoto; Yasuhiro Ando; Shigeaki Muto; San-E Ishikawa; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

Review 8.  Cardiac remodeling in obesity.

Authors:  E Dale Abel; Sheldon E Litwin; Gary Sweeney
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

9.  Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in South-Asians.

Authors:  Hanif Wasim; Nasser M Al-Daghri; Raja Chetty; Phillip G McTernan; A H Barnett; Sudhesh Kumar
Journal:  Cardiovasc Diabetol       Date:  2006-05-02       Impact factor: 9.951

10.  Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.

Authors:  Masaya Sakamoto; Hirofumi Suzuki; Takeshi Hayashi; Hiroyuki Iuchi; Tsuyoshi Isaka; Noriko Sakamoto; Yosuke Kayama; Katsuyoshi Tojo; Michihiro Yoshimura; Kazunori Utsunomiya
Journal:  Cardiovasc Diabetol       Date:  2012-10-03       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.